MTVA Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to MetaVia, Inc.'s net margin of 16.99%. MetaVia, Inc.'s return on equity of -196.71% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

MetaVia, Inc. has a consensus price target of $91.00, signalling upside risk potential of 5770.97%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 35.94%. Given that MetaVia, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe MetaVia, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

MetaVia, Inc. has a beta of 0.271, which suggesting that the stock is 72.937% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

MetaVia, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

MetaVia, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. MetaVia, Inc.'s net income of -$3.4M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, MetaVia, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 148.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia, Inc. is -- versus 12.08x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

BioMarin Pharmaceutical, Inc. has a net margin of -- compared to MetaVia, Inc.'s net margin of -3.91%. MetaVia, Inc.'s return on equity of -196.71% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.

MetaVia, Inc. has a consensus price target of $91.00, signalling upside risk potential of 5770.97%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 38.69%. Given that MetaVia, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe MetaVia, Inc. is more attractive than BioMarin Pharmaceutical, Inc..

MetaVia, Inc. has a beta of 0.271, which suggesting that the stock is 72.937% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.

MetaVia, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

MetaVia, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. MetaVia, Inc.'s net income of -$3.4M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, MetaVia, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 24.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia, Inc. is -- versus 4.06x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Emergent BioSolutions, Inc. has a net margin of -- compared to MetaVia, Inc.'s net margin of 22.16%. MetaVia, Inc.'s return on equity of -196.71% beat Emergent BioSolutions, Inc.'s return on equity of 14.25%.

MetaVia, Inc. has a consensus price target of $91.00, signalling upside risk potential of 5770.97%. On the other hand Emergent BioSolutions, Inc. has an analysts' consensus of $13.50 which suggests that it could grow by 23.51%. Given that MetaVia, Inc. has higher upside potential than Emergent BioSolutions, Inc., analysts believe MetaVia, Inc. is more attractive than Emergent BioSolutions, Inc..

MetaVia, Inc. has a beta of 0.271, which suggesting that the stock is 72.937% less volatile than S&P 500. In comparison Emergent BioSolutions, Inc. has a beta of 2.346, suggesting its more volatile than the S&P 500 by 134.572%.

MetaVia, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Emergent BioSolutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia, Inc. pays -- of its earnings as a dividend. Emergent BioSolutions, Inc. pays out -- of its earnings as a dividend.

MetaVia, Inc. quarterly revenues are --, which are smaller than Emergent BioSolutions, Inc. quarterly revenues of $231.1M. MetaVia, Inc.'s net income of -$3.4M is lower than Emergent BioSolutions, Inc.'s net income of $51.2M. Notably, MetaVia, Inc.'s price-to-earnings ratio is -- while Emergent BioSolutions, Inc.'s PE ratio is 8.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia, Inc. is -- versus 0.77x for Emergent BioSolutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Savara, Inc. has a net margin of -- compared to MetaVia, Inc.'s net margin of --. MetaVia, Inc.'s return on equity of -196.71% beat Savara, Inc.'s return on equity of -78.83%.

MetaVia, Inc. has a consensus price target of $91.00, signalling upside risk potential of 5770.97%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 95.52%. Given that MetaVia, Inc. has higher upside potential than Savara, Inc., analysts believe MetaVia, Inc. is more attractive than Savara, Inc..

MetaVia, Inc. has a beta of 0.271, which suggesting that the stock is 72.937% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.

MetaVia, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MetaVia, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.

MetaVia, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. MetaVia, Inc.'s net income of -$3.4M is higher than Savara, Inc.'s net income of -$29.6M. Notably, MetaVia, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MetaVia, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.